Delving into the Latest Updates on The Chemo-Sero-Therapeutic Research Institute with Synapse

Overview

Tags

Infectious Diseases

Other Diseases

Respiratory Diseases

Prophylactic vaccine

Combination vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	2

Top 5 Drug Type	Count

Prophylactic vaccine	2
Combination vaccine	1

Author: Kamei, Takashi ; Hatano, Etsuro ; Kakeji, Yoshihiro ; Takahashi, Arata ; Eguchi, Hidetoshi ; Minatoya, Kenji ; Imoto, Shigeru ; Otsuka, Masayuki ; Nogi, Hiroko ; Miyagawa, Shigeru ; Yamamoto, Takehito ; Saiki, Yoshikatsu ; Hara, Hisato ; Yamauchi, Hideko ; Yoshino, Ichiro ; Hasegawa, Kiyoshi ; Inomata, Masafumi ; Bitoh, Yuko ; Yoshizumi, Tomoharu ; Tajiri, Tatsuro ; Soga, Yoshiharu ; Mizushima, Tsunekazu ; Ishihara, Soichiro ; Shimizu, Hideyuki ; Okuyama, Hiroomi ; Saito, Aya ; Ebata, Tomoki ; Kato, Tatsuya ; Matsubara, Hisahiro ; Baba, Hideo ; Taketomi, Akinobu

1

News (Medical) associated with The Chemo-Sero-Therapeutic Research Institute

26 Oct 2009

·www.astellas.com

Astellas to Terminate the Development of Anti-Human Osteopontin Antibody ASK8007for RA

Japan, October 26, 2009 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that it has decided to terminate the development of ASK8007 (development code), anti-human osteopontin antibody for rheumatoid arthritis (RA). It was co-developed with Chemo-Sero-Therapeutic Research Institute (“KAKETSUKEN”; headquarters: Kumamoto, Kumamoto Prefecture). Astellas and Immuno-Biological Laboratories Co., Ltd. (headquarters: Takasaki, Gunma Prefecture) concluded a worldwide licensing agreement which granted Astellas the exclusive rights to develop, manufacture, and market anti-human osteopontin antibodies, for therapeutic use in March 2006. Astellas and KAKETSUKEN carried out Phase I for ASK8007 for RA; however, have concluded terminating the development for the field of RA by evaluating the result of the study comprehensively. Astellas is now considering a possible application of it to other indications than RA. ####

License out/inPhase 1

100 Deals associated with The Chemo-Sero-Therapeutic Research Institute

Login to view more data

100 Translational Medicine associated with The Chemo-Sero-Therapeutic Research Institute

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 13 Aug 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

2

6

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

DTaP-hepatitis B vaccine(The Chemo-Sero-Therapeutic Research Institute)	Hepatitis B More	Approved
H5N1 influenza vaccine(The Chemo-Sero-Therapeutic Research Institute)	Influenza, Human More	Approved
DTaP poliovirus vaccine(The Chemo-Sero-Therapeutic Research Institute)	Whooping Cough More	Discontinued
ASK-8007 ( OPN )	Bone Diseases More	Discontinued
Influenza virus vaccine trivalent(The Chemo-Sero-Therapeutic Research Institute)	Influenza, Human More	Discontinued